Nordic.

Methods	Multicentre randomised controlled trial. Generation of allocation schedule truly random (personal communication with investigator).
Participants	183 patients with noncurable, asymptomatic colorectal cancer who have received no previous cytostatic therapy. Age <= 75 years. Normal kidney function, no icterus, no evidence of ascites or pleural effusion
Interventions	Methotrexate (250mg/m2 infusion over 2 hours) + 5‐Fluorouracil (500mg/m2 iv bolus x 2) + Leucovorin rescue (15mg IM followed by seven oral doses of 15mg). Treatment repeated every 14 days for 8 courses, every 3 weeks for 2 courses and every 4 weeks for 2 courses. Therapy continued for 12 courses (6 months) unless tumour progression or severe adverse effects vs Primary expectancy. Chemotherapy was allowed when patients became symptomatic.
Outcomes	Survival, Symptom‐free survival, Progression, Tumour response, Toxicity Quality of life was studied in a subset at one centre
Notes	51/90 patients in supportive care group received chemotherapy when became symptomatic. Analysis by intention to treat.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate